ciraparantag
ciraparantag: developed by 1 company · 3 clinical trials tracked.
ciraparantag evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
How could ciraparantag → AMAG affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| AMAG PHARMACEUTICALS, INC. (AMAG) Healthy | Phase 2 |
Clinical Trials (3)
A Phase 2 Randomized, Double-blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Ciraparantag for Reversal of Anticoagulation in Healthy Adults
Primary endpoint: Subjects Achieving WBCT ≤120% of Baseline
Phase 2 Placebo-Controlled, Single-Site, Single-Blind Study of Apixaban Reversal by Ciraparantag as Measured by WBCT
Primary endpoint: Subjects Achieving Complete Reversal of Anticoagulation (WBCT is ≤ 110% of Baseline)
Phase 2 Placebo-Controlled, Single-Site, Single-Blind Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT
Primary endpoint: Subjects Achieving Complete Reversal of Anticoagulation (WBCT is ≤ 110% of Baseline)
Frequently asked questions
Who is developing ciraparantag?
ciraparantag is being developed by AMAG PHARMACEUTICALS, INC..
How many clinical trials involve ciraparantag?
BioSniper tracks 3 clinical trials involving ciraparantag.